In recent years, the battery of novel promising antiatherogenic tools has been expanded by theemerging nanoparticle technology. Nanoparticles have been present in the scientific literature for at least 40 years, but the field has exploded in the last decade to produce a large number of chemically different structures. Lipoprotein-mimicking nanoparticles and engineered lipoproteins are valuablepromising tools for cardiovascular prevention and therapy.
Trojan horses for drugs: a new role for lipoproteins?
CICCARELLA, GiuseppePrimo
;
2016-01-01
Abstract
In recent years, the battery of novel promising antiatherogenic tools has been expanded by theemerging nanoparticle technology. Nanoparticles have been present in the scientific literature for at least 40 years, but the field has exploded in the last decade to produce a large number of chemically different structures. Lipoprotein-mimicking nanoparticles and engineered lipoproteins are valuablepromising tools for cardiovascular prevention and therapy.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
